-

Avenacy to Attend J.P. Morgan 44th Annual Healthcare Conference

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.

At the conference, Jeff Yordon, Co-Founder & CEO and Joe Mase, Chief Operating Officer, will meet with investors to highlight the Company’s recent accomplishments, and to share the management team’s strategic direction. Those wishing to schedule a meeting are encouraged to contact FTI Capital Advisors at FTI.AvenacyTeam@fticonsulting.com.

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit https://www.avenacy.com.

Contacts

Media Contact
FTI Consulting
Avenacy@fticonsulting.com

Industry:

Avenacy

Release Versions
English

Contacts

Media Contact
FTI Consulting
Avenacy@fticonsulting.com

More News From Avenacy

Avenacy to Attend 2025 ASHP Midyear Clinical Meeting and Exhibition

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2025 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition in Las Vegas, Nevada from December 7-10, 2025. At the conference, the Avenacy leadership team will connect with existing and potential customers to share the progress the Company has made over the past two years. Interested par...

Avenacy to Highlight 2025 Achievements and Partnership Opportunities at CPHI Frankfurt

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending CPHI Frankfurt 2025, taking place October 28th-30th. “This month marks two years since Avenacy’s inception, and we are proud of the remarkable progress we have made in this short timeframe, with one of the fastest-growing injectable portfolios in the industry,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “As we begin...

Avenacy Announces Launch of Lidocaine Hydrochloride Injection, USP in the U.S. Market

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of their first Lidocaine Hydrochloride Injection, USP in the United States. The product is a generic equivalent of XYLOCAINE®, as approved by the U.S. Food and Drug Administration, and is indicated for the production of local or regional anesthesia or analgesia. Each vial of 1% Lidocaine HCl Injection, USP contains 500 mg per 50 mL (10 m...
Back to Newsroom